{"id":53811,"date":"2023-02-09T23:02:03","date_gmt":"2023-02-09T22:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/"},"modified":"2023-02-09T23:02:03","modified_gmt":"2023-02-09T22:02:03","slug":"biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/","title":{"rendered":"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call"},"content":{"rendered":"
\n

IRVING, Texas–(BUSINESS WIRE)–Biote Corp. (Nasdaq: BTMD) (\u201cBiote\u201d or the \u201cCompany\u201d), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm\u2019s results will be held Wednesday, March 29, 2023 at 8:30 a.m. ET.\n<\/p>\n

\nConference Call Details<\/b>\n<\/p>\n

\nThe conference call may be accessed by dialing (866) 524-3160 (U.S toll-free) or (412) 317-6760 (International). The live webcast of the call can be accessed using the following link: Biote Corp. Fourth Quarter and Full Year Earnings Call<\/a>. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, found here<\/a>, shortly after the event concludes.\n<\/p>\n

\nAbout Biote<\/b>\n<\/p>\n

\nBiote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words \u201cmay,\u201d \u201ccan,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201ctarget,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201congoing,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cwould\u201d and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers\u2019 reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers\u2019 sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the unpredictability of the effects of the COVID-19 pandemic; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and\/or competitive factors and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d section of the Registration Statement on Form S-1, filed with the SEC on December 12, 2022, Biote\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Press@biote.com<\/a><\/p>\n

Investors<\/b>
IR@biote.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVING, Texas–(BUSINESS WIRE)–Biote Corp. (Nasdaq: BTMD) (\u201cBiote\u201d or the \u201cCompany\u201d), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53811","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVING, Texas–(BUSINESS WIRE)–Biote Corp. (Nasdaq: BTMD) (\u201cBiote\u201d or the \u201cCompany\u201d), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T22:02:03+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call\",\"datePublished\":\"2023-02-09T22:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/\"},\"wordCount\":654,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/\",\"name\":\"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-09T22:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call - Pharma Trend","og_description":"IRVING, Texas–(BUSINESS WIRE)–Biote Corp. (Nasdaq: BTMD) (\u201cBiote\u201d or the \u201cCompany\u201d), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-09T22:02:03+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call","datePublished":"2023-02-09T22:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/"},"wordCount":654,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/","url":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/","name":"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-09T22:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biote-schedules-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53811"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53811\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}